Duopharma focuses on generic, biosimilar sectors

In terms of volume shipment, Duopharma Biotech Bhd (Duopharma) claims to be the largest pharmaceutical company in Malaysia.

However, it comes in second in terms of value behind Pfizer Malaysia, mainly because it focuses on the generic and biosimilar market rather than the so-called innovator market (the creation of new drugs).

The former commands higher volumes but garners lower prices. Nonetheless, Duopharma plans to stay the course rather than switch its focus to the innovator-led market.

Generic and biosimilars are drugs which are equivalent or almost identical to original drugs. (Small molecule drugs are known as generics while biosimilars are large molecule drugs.)

Source : Focus Malaysia